Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rociletinib hydrobromide is an orally delivered inhibitor of the mutant form of EGFR kinase (Kis: 21.5 nM and 303.3 nM for EGFR L858R/T790M and EGFR WT).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 5 days | $ 39.00 | |
10 mg | 5 days | $ 67.00 | |
1 mL * 10 mM (in DMSO) | 5 days | $ 55.00 |
Description | Rociletinib hydrobromide is an orally delivered inhibitor of the mutant form of EGFR kinase (Kis: 21.5 nM and 303.3 nM for EGFR L858R/T790M and EGFR WT). |
Targets&IC50 | EGFR (T790M):303.3 nM (ki), EGFR (L858R/T790M):21.5 nM (ki) |
In vitro | Rociletinib resistant NSCLC cell lines are sensitive to AKT inhibition. Rociletinib selectively inhibits the growth of NSCLC cells expressing mutant EGFR and induces apoptosis. Rociletinib (0.1 μM) inhibits EGFR potently and irreversibly. It inhibits more than 50% of 23 targets. |
In vivo | Rociletinib (50 mg/kg bid, p.o.) shows anti-tumor activity in human EGFR-L858R and EGFR-L858R-T790M expressing transgenic mice. Rociletinib (100 mg/kg/day, p.o.) displays anti-tumor activity in NSCLC EGFR mutant xenograft models. |
Synonyms | AVL-301 hydrobromide, CO-1686 (hydrobromide), CNX-419 hydrobromide |
Molecular Weight | 636.46 |
Formula | C27H29BrF3N7O3 |
CAS No. | 1446700-26-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 59 mg/mL (92.70 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Rociletinib hydrobromide 1446700-26-0 Others AVL-301 Hydrobromide AVL-301 hydrobromide CNX 419 Hydrobromide CO 1686 AVL301 Hydrobromide CO-1686 (hydrobromide) CO-1686 CNX-419 Hydrobromide Rociletinib Hydrobromide CO1686 CNX419 Hydrobromide CNX-419 hydrobromide AVL 301 Hydrobromide inhibitor inhibit